Inhaled treprostinil for interstitial lung disease-associated pulmonary hypertension: a silver lining on a very dark cloud

Eur Respir J. 2023 Jun 29;61(6):2300944. doi: 10.1183/13993003.00944-2023. Print 2023 Jun.

Authors

Vincent Cottin¹, Claudia Valenzuela², Marc Humbert³

Affiliations

¹ National Reference Centre for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, ERN-LUNG, UMR 754, Claude Bernard University Lyon 1, Lyon, France vincent.cottin@chu-lyon.fr.
² Hospital Universitario de la Princesa, Universidad Autonoma de Madrid, Madrid, Spain.
³ National Reference Center for Pulmonary Hypertension, Bicêtre Hospital (AP-HP), ERN-LUNG, Inserm 999, University Paris Saclay, Le Kremlin-Bicêtre, France.

PMID: 37385654
DOI: 10.1183/13993003.00944-2023

No abstract available

Publication types

Editorial

MeSH terms

Humans
Hypertension, Pulmonary* / complications
Hypertension, Pulmonary* / drug therapy
Lung Diseases, Interstitial* / complications
Lung Diseases, Interstitial* / drug therapy

Substances

treprostinil